Merck | MRK - Pre Tax Profit


Merck reported $-3.53B in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
AbbVie USD 7.61B 2.04B Jun/2026
Abbott USD 2.39B 27M Mar/2026
ALKERMES USD -61.93M 122.3M Mar/2026
Amgen USD 2.08B 570M Mar/2026
AstraZeneca USD 4.81B 894M Jun/2026
Biogen USD 647.3M 269.6M Jun/2026
Bristol-Myers Squibb USD 4.99B 1.75B Jun/2026
Coherus Biosciences USD -46.35M 90.86M Dec/2025
Drreddys Laboratories INR 2B 13.43B Mar/2026
Eli Lilly USD 8.85B 583.8M Mar/2026
Gilead Sciences USD -7.53B 10.11B Jun/2026
GlaxoSmithKline GBP 2.68B 532M Jun/2026
Glaxosmithkline GBP 2.14B 312M Mar/2026
J&J USD 8.66B 839M Jun/2026
Medtronic USD 2.26B 190M Jun/2026
Merck USD -3.53B 6.95B Mar/2026
Novartis USD 4.27B 430M Jun/2026
Novartis USD 3.84B 1.33B Mar/2026
Novo Nordisk DKK 33.8B 3.23B Jun/2025
Pacira USD 5M 4.43M Mar/2026
Perrigo USD 105.4M 513.9M Jun/2026
Pfizer USD -653M 5.84B Jun/2026
Phibro Animal Health USD 38.62M 1.26M Dec/2025
Prestige Brands USD 64.77M 2.96M Mar/2026
Regeneron Pharmaceuticals USD 1.53B 696.6M Jun/2026
Roche Holding CHF 11.17B 6.38B Jun/2026
Sanofi EUR 837M 1.17B Jun/2026
Sanofi EUR 2B 3.16B Mar/2026
United Therapeutics USD 372.7M 54.4M Jun/2026
Zoetis USD 758M 3M Mar/2026